SAN DIEGO, March 14, 2018 — Medical Marijuana, Inc. (OTC:MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® Brazil, which was the first company authorized by Anvisa to import a cannabidiol-based product to Brazil, is partnering with the National Association of Cannabidiol Users (ANUC) to host the Cannabidiol (CBD) Symposium from March 19-23 in Rio Grande do Sul, in the cities of Canoas, Passo Fundo and Porto Alegre.
It is the first time that hospitals in Brazil have ever offered cannabis events to the medical community.
On March 19, Dr. Jorge Luiz Winckler, Regent Professor of Neurology at ULBRA, is hosting an evening lecture at the University of Canoas on his clinical study on CBD as a treatment for Parkinson’s patients. This study is being developed in partnership with HempMeds® Brazil and Dr. Kelson James Almeida, neurologist and current technical director of the Integrated Rehabilitation Center (CEIR).
On March 20, Pediatric Neurologist Dr. Luiz Fernando Fonseca will be hosting accredited classes at the University of Canoas ULBRA hospital on the endocannabinoid system and CBD as a treatment option.
On March 21 in Passo Fundo, Dr. Alan Fröhlich, neurologist of the Service of Neurology and Neurosurgery and Dr. Daniel Lima Varela, Professor of Neurology at IMED and Coordinator at the Outpatient Clinic Hospital in São Vicente de Paulo, and Dr. Stuart Titus, CEO of Medical Marijuana Inc., parent company of HempMeds® Brazil, will give a presentation on the health and wellness benefits of CBD.
On March 23, the last of the three symposium events will take place in Porto Alegre in the auditorium of the Moinhos de Vento Hospital, where Dr. Pablo Winckler, neurologist and specialist in diabetic neuropathy, will give a closing presentation.
“We want to encourage a discussion of the benefits of cannabis and expand access to CBD in Brazil,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “Our relationship with Brazilian health professionals is growing daily and we hope to continue to be a helpful resource for them.”
For more information and to register, visit hempmeds.com.br/beneficios-do-cbd-rio-grande-do-sul/.
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.
About HempMeds® Brazil
HempMeds® Brazil was the first company to receive approval from the National Sanitary Surveillance Agency (Anvisa) to import a product based on cannabidiol, a substance derived from hemp, a plant of the genus Cannabis. Currently, it is authorized to supply its products, which help in the control of diseases such as epilepsy, Parkinson’s, chronic pain and multiple sclerosis, under medical prescription. For these indications, the products can be subsidized by the Brazilian government. HempMeds® Brazil works on additional approvals for other indications. About HempMeds® Brazil and all its products with natural hemp oil: www.hempmeds.com.br.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
LEGAL DISCLOSURE
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
CONTACT:
Public Relations Contact:
Andrew Hard
Chief Executive Officer CMW Media
P. 858-264-6600
